{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T01:00:09Z","timestamp":1775091609057,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40266-025-01248-8","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T12:44:55Z","timestamp":1757076295000},"page":"945-951","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting IL-6 Signaling: Safety and Effectiveness in Older Patients with Rheumatoid Arthritis"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4330-5782","authenticated-orcid":false,"given":"Hideto","family":"Kameda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reina","family":"Maezawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuto","family":"Minegishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Imaizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaharu","family":"Katagiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehisa","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"1248_CR1","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.immuni.2019.03.026","volume":"50","author":"S Kang","year":"2019","unstructured":"Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting interleukin-6 signaling in clinic. Immunity. 2019;50:1007\u201323.","journal-title":"Immunity"},{"key":"1248_CR2","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/mr\/roac073","volume":"33","author":"H Kameda","year":"2023","unstructured":"Kameda H, Nishida K, Nanki T, Watanabe A, Oshima Y, Momohara S. Safety and effectiveness of certolizumab pegol in Japanese patients with rheumatoid arthritis: results from a 24-week post-marketing surveillance study. Mod Rheumatol. 2023;33:460\u201371.","journal-title":"Mod Rheumatol"},{"key":"1248_CR3","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1093\/mr\/roae019","volume":"34","author":"H Kameda","year":"2024","unstructured":"Kameda H, Nishida K, Nanki T, Watanabe A, Oshima Y, Momohara S. Safety and effectiveness of certolizumab pegol in Japanese patients with rheumatoid arthritis: up to 3-year results from a postmarketing surveillance study. Mod Rheumatol. 2024;34:1103\u201314.","journal-title":"Mod Rheumatol"},{"key":"1248_CR4","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/mr\/roab003","volume":"32","author":"K Ebina","year":"2022","unstructured":"Ebina K. Drug efficacy and safety of biologics and Janus kinase inhibitors in elderly patients with rheumatoid arthritis. Mod Rheumatol. 2022;32:256\u201362.","journal-title":"Mod Rheumatol"},{"key":"1248_CR5","volume":"2013","author":"G Montoya-Ortiz","year":"2013","unstructured":"Montoya-Ortiz G. Immunosenescence, aging, and systemic lupus erythematosus. Autoimmune Dis. 2013;2013:267078.","journal-title":"Autoimmune Dis"},{"key":"1248_CR6","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41584-022-00863-8","volume":"18","author":"G Alsaleh","year":"2022","unstructured":"Alsaleh G, Richter FC, Simon AK. Age-related mechanisms in the context of rheumatic disease. Nat Rev Rheumatol. 2022;18:694\u2013710.","journal-title":"Nat Rev Rheumatol"},{"key":"1248_CR7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1378\/chest.07-2114","volume":"133","author":"SK Mathur","year":"2008","unstructured":"Mathur SK, Schwantes EA, Jarjour NN, Busse WW. Age-related changes in eosinophil function in human subjects. Chest. 2008;133:412\u20139.","journal-title":"Chest"},{"key":"1248_CR8","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/cea.12073","volume":"43","author":"T Nagasaki","year":"2012","unstructured":"Nagasaki T, Matsumoto H, Nakaji H, Niimi A, Ito I, Oguma T, et al. Smoking attenuates the age-related decrease in IgE levels and maintains eosinophilic inflammation. Clin Exp Allergy. 2012;43:608\u201315.","journal-title":"Clin Exp Allergy"},{"key":"1248_CR9","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1084\/jem.20190344","volume":"216","author":"S Spencer","year":"2019","unstructured":"Spencer S, Bal SK, Allen HL, Raza SI, Ma CA, G\u00fcrel M, et al. Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses. J Exp Med. 2019;216:1986\u201398.","journal-title":"J Exp Med"},{"key":"1248_CR10","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/17512433.2022.2097905","volume":"15","author":"M Narazaki","year":"2022","unstructured":"Narazaki M, Kishimoto T. Current status and prospects of IL-6-targeting therapy. Exp Rev Clin Pharmacol. 2022;15:575\u201392.","journal-title":"Exp Rev Clin Pharmacol"},{"key":"1248_CR11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","volume":"69","author":"G Jones","year":"2010","unstructured":"Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88\u201396.","journal-title":"Ann Rheum Dis"},{"key":"1248_CR12","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","volume":"381","author":"C Gabay","year":"2013","unstructured":"Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381:1541\u201350.","journal-title":"Lancet"},{"key":"1248_CR13","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2008.092866","volume":"68","author":"N Nishimoto","year":"2009","unstructured":"Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009;68:1580\u20134.","journal-title":"Ann Rheum Dis"},{"key":"1248_CR14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/keq343","volume":"50","author":"L Campbell","year":"2011","unstructured":"Campbell L, Chen C, Bhagat SS, Parker RA, \u00d6st\u00f6r AJK. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systemic literature review and meta-analysis of randomized controlled trials. Rheumatology. 2011;50:552\u201362.","journal-title":"Rheumatology"},{"key":"1248_CR15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00296-017-3870-7","volume":"38","author":"L Baganz","year":"2018","unstructured":"Baganz L, Richter A, Kekow J, Bussmann A, Krause A, Stille C, et al. Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort. Rheumatol Int. 2018;38:579\u201387.","journal-title":"Rheumatol Int"},{"key":"1248_CR16","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/rheumatology\/kex238","volume":"56","author":"J Morel","year":"2017","unstructured":"Morel J, Constantin A, Baron G, Dernis E, Flipo RM, Rist S, et al. Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French registry REGATE. Rheumatology. 2017;56:1746\u201354.","journal-title":"Rheumatology"},{"key":"1248_CR17","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1136\/ard.2011.151092","volume":"70","author":"T Koike","year":"2011","unstructured":"Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis. 2011;70:2148\u201351.","journal-title":"Ann Rheum Dis"},{"key":"1248_CR18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3899\/jrheum.130466","volume":"41","author":"T Koike","year":"2014","unstructured":"Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol. 2014;41:15\u201323.","journal-title":"J Rheumatol"},{"key":"1248_CR19","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1080\/14397595.2017.1416760","volume":"28","author":"T Atsumi","year":"2018","unstructured":"Atsumi T, Fujio K, Yamaoka K, Tomobe M, Kuroyanagi K, Kameda H. Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting. Mod Rheumatol. 2018;28:780\u20138.","journal-title":"Mod Rheumatol"},{"key":"1248_CR20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13075-020-02233-9","volume":"22","author":"A Kawabe","year":"2020","unstructured":"Kawabe A, Nakano K, Kubo S, Asakawa T, Tanaka Y. Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry. Arthritis Res Ther. 2020;22:136.","journal-title":"Arthritis Res Ther"},{"key":"1248_CR21","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/annrheumdis-2016-210297","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Choy E, Kivitz A, Ogata A, Bao M, Nomura A, et al. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76:1078\u201385.","journal-title":"Ann Rheum Dis"},{"key":"1248_CR22","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","volume":"31","author":"V Strand","year":"2017","unstructured":"Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31:299\u2013316.","journal-title":"BioDrugs"},{"key":"1248_CR23","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1136\/annrheumdis-2013-204405","volume":"73","author":"TW Huizinga","year":"2014","unstructured":"Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, et al. Sarilumab, a fully human monoclonal antibody against IL-6Ra in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY part A trial. Ann Rheum Dis. 2014;73:1626\u201334.","journal-title":"Ann Rheum Dis"},{"key":"1248_CR24","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.39093","volume":"67","author":"MC Genovese","year":"2015","unstructured":"Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase \u2162 study. Arthritis Rheumatol. 2015;67:1424\u201337.","journal-title":"Arthritis Rheumatol"},{"key":"1248_CR25","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomized, double-blind, parallel-group phase \u2162 trial. Ann Rheum Dis. 2017;76:840\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1248_CR26","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/art.39944","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, Hrycaj P, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2017;69:277\u201390.","journal-title":"Arthritis Rheumatol"},{"key":"1248_CR27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13075-019-1856-4","volume":"21","author":"Y Tanaka","year":"2019","unstructured":"Tanaka Y, Wada K, Takahashi Y, Hagino O, van Hoogstraten H, Graham NMH, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase \u2162 trial in Japan. Arthritis Res Ther. 2019;21:79.","journal-title":"Arthritis Res Ther"},{"key":"1248_CR28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/14397595.2019.1639939","volume":"30","author":"H Kameda","year":"2020","unstructured":"Kameda H, Wada K, Takahashi Y, Hagino O, van Hoogstraten H, Graham N, et al. Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: a Japan phase 3 trial (HARUKA). Mod Rheumatol. 2020;30:239\u201348.","journal-title":"Mod Rheumatol"},{"key":"1248_CR29","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/mr\/road055","volume":"34","author":"H Kameda","year":"2024","unstructured":"Kameda H, Tasaka S, Takahashi T, Suzuki K, Soeda N, Tanaka Y. Safety and effectiveness of sarilumab in Japanese patients with rheumatoid arthritis refractory to previous treatments: an interim analysis of a post-marketing surveillance. Mod Rheumatol. 2024;34:444\u201352.","journal-title":"Mod Rheumatol"},{"key":"1248_CR30","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/mr\/roae051","volume":"35","author":"H Kameda","year":"2025","unstructured":"Kameda H, Tasaka S, Takahashi T, Suzuki K, Soeda N, van Hoogstranten H, et al. Safety of sarilumab in Japanese population with rheumatoid arthritis by age group: data from an interim analysis of a post-marketing surveillance study. Mod Rheumatol. 2025;35:42\u20139.","journal-title":"Mod Rheumatol"},{"key":"1248_CR31","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2013-205137","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomized, (proof-of-concept and dose-finding), phase \u2161 study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2014;73:1616\u201325.","journal-title":"Ann Rheum Dis"},{"key":"1248_CR32","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0140-6736(17)30401-4","volume":"389","author":"D Aletaha","year":"2017","unstructured":"Aletaha D, Bingham CO 3rd, Tanaka Y, Agarwal P, Kurrasch R, Tak PP, et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomized, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet. 2017;389:1206\u201317.","journal-title":"Lancet"},{"key":"1248_CR33","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/annrheumdis-2017-212496","volume":"77","author":"PC Taylor","year":"2018","unstructured":"Taylor PC, Schiff MH, Wang Q, Jiang Y, Zhuang Y, Kurrasch R, et al. Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-na\u00efve patients with active rheumatoid arthritis (SIRROUND-H): a randomized, double-blind, parallel-group, multinational, 52-week, phase 3 study. Ann Rheum Dis. 2018;77:658\u201366.","journal-title":"Ann Rheum Dis"},{"key":"1248_CR34","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1002\/art.39249","volume":"67","author":"ME Weinblatt","year":"2015","unstructured":"Weinblatt ME, Mease P, Mysler E, Takeuchi T, Drescher E, Berman A, et al. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase \u2161b, randomized, double-blind, placebo\/active-controlled, dose-raging study. Arthritis Rheumatol. 2015;67:2591\u2013600.","journal-title":"Arthritis Rheumatol"},{"key":"1248_CR35","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1136\/annrheumdis-2013-204760","volume":"73","author":"MC Genovese","year":"2014","unstructured":"Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomized phase \u2161b study. Ann Rheum Dis. 2014;73:1607\u201315.","journal-title":"Ann Rheum Dis"},{"key":"1248_CR36","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/annrheumdis-2021-219876","volume":"81","author":"E Nasonov","year":"2022","unstructured":"Nasonov E, Fatenejad S, Feist E, Ivanova M, Korneva E, Krechikova DG, et al. Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomized controlled phase \u2162 study. Ann Rheum Dis. 2022;81:469\u201379.","journal-title":"Ann Rheum Dis"},{"key":"1248_CR37","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1136\/ard-2022-222630","volume":"81","author":"E Feist","year":"2022","unstructured":"Feist E, Fatenejad G, Grishin S, Korneva E, Luggen ME, Nasonov E, et al. Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomized controlled phase \u2162 study. Ann Rheum Dis. 2022;81:1661\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1248_CR38","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.70202","volume":"28","author":"H Kameda","year":"2025","unstructured":"Kameda H, Maezawa R, Minegishi Y, Imaizumi C, Ogura T. Anticytokine (ligand) antibody versus antireceptor antibody in treating rheumatoid arthritis and other immune-mediated inflammatory diseases. Int J Rheum Dis. 2025;28:e70202.","journal-title":"Int J Rheum Dis"},{"key":"1248_CR39","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1002\/art.39164","volume":"67","author":"M Fujimoto","year":"2015","unstructured":"Fujimoto M, Serada S, Suzuki K, Nishikawa A, Ogata A, Nanki T, et al. Leucine rich \u03b12-glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis. Arthritis Rheumatol. 2015;67:2056\u201360.","journal-title":"Arthritis Rheumatol"},{"key":"1248_CR40","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106124","volume":"26","author":"C Chauvin","year":"2023","unstructured":"Chauvin C, Levillayer L, Roumier M, Nielly H, Roth C, Karnam A, et al. Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants. iScience. 2023;26:106124.","journal-title":"iScience"},{"key":"1248_CR41","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1136\/ard.2010.141325","volume":"70","author":"K Muhammad","year":"2011","unstructured":"Muhammad K, Roll P, Seibold T, Kleinert S, Einsele H, D\u00f6rner T, et al. Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells. Ann Rheum Dis. 2011;70:1507\u201310.","journal-title":"Ann Rheum Dis"},{"key":"1248_CR42","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2012-201950","volume":"71","author":"S Mori","year":"2012","unstructured":"Mori S, Ueki Y, Hirakata N, Oribe M, Hidaka T, Oishi K. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis. 2012;71:2006\u201310.","journal-title":"Ann Rheum Dis"},{"key":"1248_CR43","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/rheumatology\/key361","volume":"58","author":"P Emery","year":"2019","unstructured":"Emery P, Rondon J, Parrino J, Lin Y, Pena-Rossi C, van Hoogstraten H, et al. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. Rheumatology. 2019;58:849\u201358.","journal-title":"Rheumatology"},{"key":"1248_CR44","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/rheumatology\/kex060.079","volume":"56","author":"RJ Moots","year":"2017","unstructured":"Moots RJ, Sebba A, Rigby W, Ostor A, Porter-Brown B, Donaldson F, et al. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. Rheumatology. 2017;56:541\u20139.","journal-title":"Rheumatology"},{"key":"1248_CR45","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/rheumatology\/keu035","volume":"53","author":"HL Wright","year":"2014","unstructured":"Wright HL, Cross AL, Edwards SW, Moots RJ. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. Rheumatology. 2014;53:1321\u201331.","journal-title":"Rheumatology"},{"key":"1248_CR46","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/rheumatology\/keu363","volume":"54","author":"CI Da\u00efen","year":"2015","unstructured":"Da\u00efen CI, Gailhac S, Audo R, Mura T, Hahne M, Combe B, et al. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis. Rheumatology. 2015;54:601\u20138.","journal-title":"Rheumatology"},{"key":"1248_CR47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.41095","volume":"72","author":"JT Giles","year":"2020","unstructured":"Giles JT, Sattar N, Gabriel S, Ridker PM, Gay S, Warne C, et al. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol. 2020;72:31\u201340.","journal-title":"Arthritis Rheumatol"},{"key":"1248_CR48","doi-asserted-by":"crossref","first-page":"501","DOI":"10.55563\/clinexprheumatol\/hfceu3","volume":"39","author":"C Lukas","year":"2021","unstructured":"Lukas C, Redondin M, Pane I, Soubrier M, Houvenagel E, Sibilia J, et al. Cardiovascular events and change in cholesterol levels in patients with rheumatoid arthritis treated with tocilizumab: data from the REGATE registry. Clin Exp Rheumatol. 2021;39:501\u20137.","journal-title":"Clin Exp Rheumatol"},{"key":"1248_CR49","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/14397595.2013.844294","volume":"24","author":"I Miyagawa","year":"2014","unstructured":"Miyagawa I, Nakayamada S, Saito K, Hanami K, Nawata M, Sawamukai N, et al. Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis. Mod Rheumatol. 2014;24:405\u20139.","journal-title":"Mod Rheumatol"},{"key":"1248_CR50","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","volume":"54","author":"RN Maini","year":"2006","unstructured":"Maini RN, Taylor PC, Szechinski J, Pavelka K, Br\u00f6ll J, Balint G, et al. Double-blind randomized controlled trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817\u201329.","journal-title":"Arthritis Rheum"},{"key":"1248_CR51","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1136\/annrheumdis-2017-211708","volume":"76","author":"J Robertson","year":"2017","unstructured":"Robertson J, Porter D, Sattar N, Packard CJ, Caslake M, McInnes I, et al. Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. Ann Rheum Dis. 2017;76:1949\u201352.","journal-title":"Ann Rheum Dis"},{"key":"1248_CR52","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13075-020-02297-7","volume":"22","author":"E Toussirot","year":"2020","unstructured":"Toussirot E, Marotte H, Mullerman D, Cormier G, Coury F, Gaudin P, et al. Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in pateints with rheumatoid arthritis: a 12-month multicentre study. Arthritis Res Ther. 2020;22:224.","journal-title":"Arthritis Res Ther"},{"key":"1248_CR53","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3109\/s10165-010-0366-7","volume":"21","author":"H Yamanaka","year":"2011","unstructured":"Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol. 2011;21:122\u201333.","journal-title":"Mod Rheumatol"},{"key":"1248_CR54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jbspin.2014.07.010","volume":"82","author":"YM Pers","year":"2015","unstructured":"Pers YM, Schaub R, Constant E, Lambert J, Godfrin-Valnet M, Fortunet C, et al. Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis. Jt Bone Spine. 2015;82:25\u201330.","journal-title":"Jt Bone Spine"},{"key":"1248_CR55","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/mr\/roae057","volume":"35","author":"Y Tanaka","year":"2025","unstructured":"Tanaka Y, Takahashi T, van Hoogstraten H, Kato N, Kameda H. Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (< 65 and \u2265 65 years): a post hoc analysis of Japanese phase 3 clinical trials. Mod Rheumatol. 2025;35:34\u201341.","journal-title":"Mod Rheumatol"},{"key":"1248_CR56","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3899\/jrheum.140673","volume":"42","author":"YM Pers","year":"2015","unstructured":"Pers YM, Godfin-Valnet M, Lambert C, Constant E, Mura T, Pallot-Prades B, et al. Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient. J Rheumatol. 2015;42:580\u20134.","journal-title":"J Rheumatol"},{"key":"1248_CR57","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.semarthrit.2012.01.004","volume":"42","author":"MA Karsdal","year":"2012","unstructured":"Karsdal MA, Schett G, Emery P, Harari O, Byrjalsen I, Kenwright A, et al. IL-6 receptor inhibition positively modulate bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Semin Arthritis Rheum. 2012;42:131\u20139.","journal-title":"Semin Arthritis Rheum"},{"key":"1248_CR58","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2011-201075","volume":"72","author":"S Finzel","year":"2013","unstructured":"Finzel S, Rech J, Schmidt S, Engelke K, Englbrecht M, Schett G. Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study. Ann Rheum Dis. 2013;72:396\u2013400.","journal-title":"Ann Rheum Dis"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01248-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-025-01248-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01248-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:14:53Z","timestamp":1759158893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-025-01248-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1248"],"URL":"https:\/\/doi.org\/10.1007\/s40266-025-01248-8","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"H.K. received consulting and\/or speaker fees from AbbVie, Asahi Kasei, Bristol-Myers Squibb, Eisai, Eli Lilly, Janssen, Mitsubishi Tanabe, and UCB and research\/educational grants from Asahi Kasei, Pfizer, and Taisho. The other authors have nothing to declare in relation to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval was waived because of the nature of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All the authors provided final approval for the version to be published and agreed to be accountable for all aspects of the work.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Hideto Kameda: conception and drafting of the work; Reina Maezawa, Yasuto Minegishi, Chihiro Imaizumi, Takaharu Katagiri, and Takehisa Ogura: interpretation of data for the work and reviewing the work critically for important intellectual content.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}